Therefore, future experiments will further investigate the attenuation of p53 phosphorylation by targeting IKKβ in vivo through combination treatment using IKKβ inhibitors and glutaminase inhibitors in cancer cells harboring wild-type or mutant p53. The gene discussed is IKBKB; the disease is cancer.